International breakfast webinar: Global surveillance of cancer survival – CONCORD programme
This event is hosted by the LSHTM Cancer Survival Group, which has been examining trends and inequalities in cancer survival in the UK and other countries for 20 years.
The CONCORD programme, led by the Cancer Survival Group at the London School of Hygiene and Tropical Medicine, established global surveillance of trends in cancer survival in 2015.1 CONCORD-3, published in The Lancet in 2018,2 involved 600 collaborators, and included individual tumour records for more than 37.5 million patients with cancer, provided by 322 cancer registries in 71 countries and territories worldwide.
Since 2017, the Organisation for Economic Co-operation and Development has included CONCORD survival estimates for 48 countries in its Health at a Glance publications,3-7 among the indicators of the effectiveness of national health systems in managing cancer. This provides formal recognition by an international agency of the global coverage, methodological rigour and international comparability of the CONCORD survival estimates. CONCORD results have also been used in the European Union for its State of Health in the EU initiative, by the World Health Organisation to examine the impact of the pricing of medicines for cancer prevention and treatment,8 and in a Lancet Oncology Commission on the long-term economic benefits of delivering sustainable care for children with cancer around the world.9 The Commission will also be presented during London Global Cancer Week, on 18 November 2020.
Since 2018, more detailed analyses have been carried out of cancer survival by stage at diagnosis, most recently for breast cancer, in Health at a Glance Europe (in press).
CONCORD survival estimates have become the de facto standard for international comparisons of cancer survival, as a metric of health systems performance, cancer policy and improvement in outcomes, helping to drive cancer control policy world-wide.
Programme (please note that the time listed is Greenwich Mean Time (GMT))
- 08.00 – 08.10: Welcome and introduction
- 08.20 – 08.40: Global surveillance of cancer survival will stimulate policy and improve equity
Speaker: Professor Michel Coleman, LSHTM, London, UK
- 08.40 – 09.00: Trends and inequalities in cancer survival world-wide: the latest results
Speaker: Dr Claudia Allemani, LSHTM, London, UK
- 09.00 – 09.20: Cancer survival comparisons as a tool to improve the quality of health care: the experience from OECD
Speaker: Dr Niek Klazinga, University of Amsterdam, The Netherlands
- 09.20 – 09.40: Delivering affordable cancer care in developed and developing countries
Speaker: Professor Richard Sullivan, King's College, London, UK
- 09.40 – 10.00: Panel discussion
- Dr Claudia Allemani, Associate Professor of Cancer Epidemiology, LSHTM
Dr Claudia Allemani is an Associate Professor of Cancer Epidemiology at the London School of Hygiene and Tropical Medicine. Claudia’s academic background in Italy covers the range from applied mathematics (MSc 1996), epidemiology and medical statistics (MSc 1998 and PhD-equivalent 2001), to public health and education (PhD 2006). She was elected a Fellow of the UK Higher Education Academy (2012), and an Honorary Member of the UK Faculty of Public Health (2014). She was awarded the Faculty’s inaugural Global Public Health Award in June 2016.
Her main interests are in international comparisons of cancer survival (EUROCARE, HAEMACARE, CONCORD), “high-resolution” studies on patterns of care and short-, medium- and long-term survival, as well as the estimation of avoidable premature deaths, with a focus on their impact on cancer policy. She has 20 years’ experience in this domain. She leads the data management, quality control and survival analyses for the global surveillance of cancer survival (CONCORD programme), for which she is co-Principal Investigator.
In 2017, she obtained a prestigious European Research Council Consolidator grant (€2 million) to carry out a world-wide study on inequalities in survival from cancers of the breast, cervix and ovary (VENUSCANCER).
She has published over 70 peer-reviewed articles, and co-authored 80 more as a Working Group member. She has written 9 book chapters, manuals and reports. Her research has been cited over 11,000 times (h-index 47, i-10 index 73; Google Scholar).
She collaborates with the Organisation for Economic Co-operation and Development (OECD), and with several other international agencies focused on cancer control, including the International Atomic Energy Agency (IAEA), the World Health Organisation (WHO), the US Centers for Disease Control and Prevention (CDC), the American Cancer Society (ACS) and the French National Cancer Institute (INCa), as well as the European Cancer Patient Coalition (ECPC). She has recently contributed to the Digestive Cancers Europe task force to establish a “Roadmap for Colorectal Cancer in Europe”.
- Professor Michel P Coleman, Professor of Epidemiology and Vital Statistics , LSHTM
Michel qualified in medicine in Oxford last century, and practised in hospital medicine and general practice, later becoming an epidemiologist. He has been Professor of Epidemiology and Vital Statistics at the London School of Hygiene and Tropical Medicine (LSHTM) since 1995; Head of the Cancer Survival Group at LSHTM since 2005, and Honorary Consultant in Oncology at UCL Hospitals NHS Foundation Trust since 2012.
He has worked for the World Health Organisation at the International Agency for Research on Cancer in Lyon (1987-1991), and was Medical Director of the Thames Cancer Registry in London (1991-1995). He was Head of the Cancer and Public Health Unit (LSHTM) during 1998-2003; Deputy Chief Medical Statistician (Office for National Statistics) during 1995-2004, and Head of the WHO UK Collaborating Centre on the Classification of Diseases during 1996-2004.
He has published more than 500 articles on cancer and on public health, and has taught epidemiology in many countries. He has been involved in the issue of confidentiality and cancer surveillance for 30 years, both in the UK and internationally. His main interests include trends in cancer incidence, mortality and survival, and the application of these tools to the public health control of cancer. He has been an advisor on cancer registration, cancer research and cancer control to governments in several countries, and to the European Union.
With Dr Claudia Allemani, he is co-Principal Investigator of the CONCORD programme for the global surveillance of trends in cancer survival.
- Dr Niek Klazinga, Head of the OECD Health Care Quality Indicator Programme
Niek Klazinga is the strategic lead of the Health Care Quality and Outcomes program at the OECD in Paris since 2006. He combines this work with a professorship in Social Medicine at the Academic Medical Centre at the University of Amsterdam which he holds since 1999. Dr. Klazinga has been involved over the past 30 years in numerous health services research projects and policy debates on quality of care and published widely on the subject. Previous positions include senior staff member of the Dutch Organization for Quality in Health Care (CBO), medical director of the Municipal Public Health Office of the city of Amsterdam, associate professor at the Erasmus University Rotterdam and member of the board of trustees of a teaching hospital (Isala Clinics) and mental health care institute (Arkin). Present commitments include a visiting professorship at the Corvinus University in Budapest, advisor to WHO (HQ, Euro and WPRO) advisor to the Canadian Institute for Health Informatics and member of the Quality Council of the Dutch Health Care Institute (ZiN). Dr. Klazinga has (co)authored around 250 articles in peer-reviewed journals and to date completed the supervision of 36 PhD trajectories.
- Professor Richard Sullivan, Professor of Cancer and Global Health, King's College London
Richard Sullivan is Professor of Cancer and Global Health at King’s College London, and Director of the King’s Institute of Cancer Policy and co-Director of the Conflict and Health Research Group. His research interests extend from global cancer to conflict & health. Richard has worked on a number of Lancet and Lancet Oncology commissions, currently the Lancet Commission on Global Diagnostics and the Lancet Oncology European Cancer Research Commission.
Richard’s research teams have major programs in capacity building in conflict and health, and humanitarian medicine, particularly in the Middle East and North Africa (r4hc-mena.org), as well as programmes in women’s health and cancer, digital innovation (virtual-reality enhanced surgery) and a wide range of global health security projects including on the COVID-19 pandemic and strengthening health systems in NW and NE Syria. His global cancer research programs cover cancer systems strengthening, affordability, value particularly and political economy, global radiotherapy, social welfare and cancer care in conflict. Professor Sullivan qualified in medicine and trained in surgery (urology) gaining his PhD in Biochemistry from University College London.
Richard was Clinical Director of Cancer Research UK between 1999 and 2008. He has also worked for many years on biosecurity and counterproliferation issues, including Ebola outbreaks in West Africa and DR Congo. Richard is an NCD advisor to the WHO, a member of the National Cancer Grid of India and advisor (civil-military) to Save the Children.
1. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385: 977–1010. https://doi.org/10.1016/S0140-6736(14)62038-9.
2. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023-75. https://doi.org/10.1016/S0140-6736(17)33326-3.
3. Organisation for Economic Co-operation and Development. Health at a Glance 2017: OECD indicators. Paris: OECD Publishing, 2017. https://doi.org/10.1787/health_glance-2017-en.
4. OECD/EU. Health at a Glance: Europe 2018: State of Health in the EU Cycle. Paris: OECD Publishing, 2018. https://doi.org/10.1787/health_glance_eur-2018-en.
5. OECD/WHO. Health at a Glance: Asia/Pacific 2018 - Measuring progress towards universal health coverage. Paris: OECD Publishing, 2018. https://doi.org/10.1787/health_glance_ap-2018-en.
6. Organisation for Economic Co-operation and Development. Health at a Glance 2019: OECD indicators. Paris: OECD Publishing, 2019. https://doi.org/10.1787/4dd50c09-en.
7. Organisation for Economic Co-operation and Development/The World Bank. Health at a Glance: Latin America and the Caribbean 2020. Paris: OECD, 2020. https://doi.org/10.1787/6089164f-en.
8. World Health Organisation. Pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly Resolution 70.12 Operative paragraph 2.9 on pricing approaches and their impacts on availability and affordability of medicines for the prevention and treatment of cancer. Geneva: WHO, 2018.
9. Atun R, Bhakta N, Denburg A, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol 2020; 21: 185-224. https://doi.org/10.1016/S1470-2045(20)30022-X.